| Model Number |
305U223 |
| Medical Device Problem Codes |
Calcified (1077); Device Stenosis (4066); Intravalvular regurgitation (4068)
|
| Health Effect - Clinical Codes |
Aortic Valve Stenosis (1717); Calcium Deposits/Calcification (1758); Syncope/Fainting (4411); Aortic Valve Insufficiency/ Regurgitation (4450)
|
| Date of Event |
08/28/2026
|
|
Type of Reportable Event
|
Serious Injury
|
|
Event or Problem Description
|
|
It was reported that 12 years post implant of this 23mm aortic bioprosthetic valve, the patient is being evaluated for a transcatheter valve-in-valve replacement.The reason for evaluation was reported as severe aortic central regurgitation/insufficiency, valve stenosis.It was reported that the patient also experienced a syncopal episode.No intervention or adverse patient effects were reported.
|
| |
|
Event or Problem Description
|
|
Additional information received reported that an intervention was planned for (b)(6)2026.Evidence of calcification was seen in the the left ventricular outflow tract (lvot) under right coronary cusp (rcc), left coronary cusp (lcc), and non coronary cusp (ncc).No additional adverse patient effects were reported.
|
| |
|
Event or Problem Description
|
|
Additional information received reported that on (b)(6) 2026 the patient had a 23mm aortic transcatheter valve-in-valve replacement.No additional adverse patient effects were reported.
|
| |
|
Additional Manufacturer Narrative
|
|
Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Additional Manufacturer Narrative
|
|
B2m, b5 and h6 codes were updated.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Additional Manufacturer Narrative
|
|
B2, b5 and imf (annex f) code were updated.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Search Alerts/Recalls
|